FibroGen (FGEN) provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from roxadustat Phase 3 program for the treatment of anemia of CKD

Go back to FibroGen (FGEN) provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from roxadustat Phase 3 program for the treatment of anemia of CKD
(NASDAQ: FGEN) Delayed: 20.27 -1.29 (5.98%)
Previous Close $21.56    52 Week High $31.90 
Open $21.07    52 Week Low $14.38 
Day High $21.65    P/E N/A 
Day Low $20.24    EPS $0.00 
Volume 884,926